ArticleBMC gastroenterology2025
Estimating the costs of delayed Celiac disease diagnosis.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Mass Screening Strategies for Celiac Disease in Apparently Healthy Children and Adolescents: A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCeliac disease (CD) is a chronic immune-mediated disorder that can lead to significant health complications and economic burdens resulting from delayed diagnosis. This study aims to estimate the potential costs associated with delayed CD diagnosis in Iran.
methodsA cross-sectional survey was conducted with 375 CD patients across various provinces in Iran from March to July 2024. Participants provided self-reported data on demographics, medical history, diagnostic procedures, symptom onset, healthcare visits, and associated expenses. Two cost estimation methods were used: (1) modeled costs based on healthcare utilization frequencies multiplied by 2024 unit costs (Iranian Ministry of Health tariffs and diagnostic center data), and (2) self-reported costs including direct medical expenses and indirect costs like lost productivity. Additionally, linear regression models were used to identify factors associated with higher total costs.
resultsThe median age of participants was 30 years, with the majority being women (71.20%) and single (52.27%). The median diagnostic delay of CD was approximately 10 years. Patients reported an average of 7.34 visits to general practitioners and 4.61 to specialists prior to diagnosis. The total self-reported economic burden reached an average of 45.87 million Toman (~ 573 USD), with a median of 19.75 million Toman (~ 247 USD). Modeled cost estimates based on healthcare utilization revealed total costs averaging 67.59 million Toman (~ 849 USD), with a median of 37.71 million Toman (~ 474 USD). Hospitalizations triggered by complications related to delayed diagnosis occurred in 24.27% of participants. Geographically, the proportion of CD cases was highest in Razavi Khorasan, Kerman, and Gilan, with a notable increase in diagnoses from 1984 to 2024. Subgroup analysis showed that married participants, those with higher education, and those who were self-employed or employed reported higher median costs. Regression analysis further confirmed that being married and having longer adherence to a gluten-free diet (GFD) were independently associated with increased total costs.
conclusionThe prolonged diagnostic delay for CD in Iran leads to substantial healthcare costs and is associated with significant morbidity. These costs are disproportionately higher among certain subgroups, including married individuals and those with longer adherence to a GFD. To address this, implementing widespread screening, improving healthcare provider education, and increasing public awareness are essential strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.